Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL
Pediatric Blood & Cancer · 2026
DOI: 10.1002/1545-5017.70547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Miguel Vieira Martins und 14 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Myeloid-Lymphoid Leukemia Protein, Antibodies, Bispecific, Gene Rearrangement. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon Europe/Marie Skłodowska-Curie Action co-fund, Australian Government's Medical Research Future Fund, Bornecancerfonden.
Abstract (Originalsprache)
Adding blinatumomab to standard chemotherapy for infants with KMT2A ‐rearranged acute B‐cell lymphoblastic leukemia ( KMT2A ‐r B‐ALL) improves outcomes. Although blinatumomab impairs immunoglobulin G (lgG) production, increasing infection susceptibility, IgG recovery remains poorly understood. Thirty infants received Interfant‐06 protocol chemotherapy with one course of blinatumomab added post‐induction. We screened 169 IgG levels post‐blinatumomab and IVIg supplementation timepoints. An increase in IgG was subsequently noted until maintenance, where practically all available values returned to normal (>4 g/L). Blinatumomab leads to an IgG reduction, with near‐complete recovery occurring before end of treatment. Future trials should monitor immunoglobulin recovery post‐blinatumomab to guide infection‐preventing strategies. Trial Registration : EudraCT no: 2016‐004674‐17
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Australian and New Zealand Children's Hematology and Oncology Group, Perth, Western Australia, Australia.
- Perth Children's Hospital and University of Western Australia, Perth, Western Australia, Australia.
- Curtin Medical School, Curtin University, Perth, Western Australia, Australia.
ORCID-Profile: Miguel Vieira Martins, Rishi S Kotecha, Karsten Nysom, Jan Stary, Franco Locatelli, Inge M van der Sluis
Förderung
- Horizon Europe/Marie Skłodowska-Curie Action co-fund
- Australian Government's Medical Research Future Fund
- Bornecancerfonden
- Societé Française de lutte contre les Cancers et les leucémies de l´Enfant et de l'Adolescent
- Fédération Enfants et Santé
- St. Anna Children's research Institute
- Princess Maxima Foundation
- Erasmus MC Sophia Foundation
Zitieren
APA
Vieira Martins, M., de Lorenzo, P., Kotecha, R. S., Attarbaschi, A., Escherich, G., Nysom, K., Stary, J., Ferster, A., Brethon, B., Locatelli, F., Schrappe, M., Houtem, P. E. S., Valsecchi, M. G., Pieters, R., & van der Sluis, I. M. (2026). Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70547
Vancouver
Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70547
BibTeX
@article{VieiraMartins2026,
author = {Vieira Martins, Miguel and de Lorenzo, Paola and Kotecha, Rishi S and Attarbaschi, Andishe and Escherich, Gabriele and Nysom, Karsten and Stary, Jan and Ferster, Alina and Brethon, Benoit and Locatelli, Franco and Schrappe, Martin and Houtem, Peggy E Scholte-van and Valsecchi, Maria G and Pieters, Rob and van der Sluis, Inge M},
title = {Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A‐Rearranged ALL},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70547}
}
EUVIMED